Search

Displaying results 571 - 580 of 10000 in total
  1. Drug

    Peginterferon alfa-2b

    go.drugbank.com/drugs/DB00022
    ApprovedInvestigational

    Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. … Approved in 2001 by the FDA, Pegintron is indicated for the treatment of HCV with [Ribavirin] or other antiviral drugs [FDA Label].

    Products: เพ็คอินทรอน (100 mcg/vial), PEG-INTRON CLEARCLICK FOR INJECTION 100 mcg/0.5 ml
  2. Drug

    Ursodeoxycholic acid

    go.drugbank.com/drugs/DB01586
    ApprovedInvestigational

    [A256272] UDCA works by replacing the hydrophobic or more toxic bile acids from the bile acid pool.[A256272] … [A256272] UDCA was first approved by the FDA in 1987 for dissolution of gallstones and for primary biliary cirrhosis in 1996.

    Products: URSOMED 250 MG/5 ML ORAL SÜSPANSİYON, 100 ML, URSOMED 150 MG KAPSÜL (CHOLUDEXAN), 100 KAPSÜL
  3. Drug

    Cefalotin

    go.drugbank.com/drugs/DB00456
    ApprovedVet approvedWithdrawn

    Cefalotin is a cephalosporin antibiotic.

    Products: KEFOLITIN 1 G/10 ML IV/IM ENJEKTABL FLAKON, CEFAZOLINA PARA INYECCION 1000 MG
  4. Drug

    Sodium zirconium cyclosilicate

    go.drugbank.com/drugs/DB14048
    ApprovedInvestigational

    [L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and … [L2933] The treatment effect was maintained for up to 12 months.[L2933]

    Products: SIMKELMA 10 G ORAL SÜSPANSİYON HAZIRLAMAK İÇİN TOZ, 11 ADET, SIMKELMA 10 G ORAL SÜSPANSİYON HAZIRLAMAK İÇİN TOZ, 28 ADET
  5. Drug

    Ambrisentan

    go.drugbank.com/drugs/DB06403
    ApprovedInvestigational

    Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve e...

    Categories: Heterocyclic Compounds, 1-RingProducts: AMBRISEN 1A PHARMA 5MG, AMBRISEN 1A PHARMA 10MG
  6. Drug

    Imipramine

    go.drugbank.com/drugs/DB00458
    ApprovedInvestigational

    They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. … TCAs also block histamine H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred

    Categories: Adrenergic alpha-1 Receptor Antagonists, Tertiary amine tricyclic antidepressantsProducts: IMIPRAMINA 10 MG, IMIPRAMIN-NEURAX 10 MG
  7. Drug

    Deoxycholic acid

    go.drugbank.com/drugs/DB03619
    ApprovedInvestigational

    In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. … It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical

    Products: BELKYRA INJECTION 10 MG/ML, Belkyra 10 mg/ml Injektionslösung
  8. Drug

    Dobutamine

    go.drugbank.com/drugs/DB00841
    ApprovedInvestigational

    A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.

    Synonyms: (±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol, 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamineMixtures: DOCARIP® 1 MG/ML
  9. Drug

    Trastuzumab

    go.drugbank.com/drugs/DB00072
    ApprovedInvestigational

    In November 2023, trastuzumab was also approved by the EMA under the brand name Herwenda.[L49339] … Kanjinti (trastuzumab-anns)[L14135] and Hercessi[L52840] are other biosimilars approved by the FDA. In Canada, biosimilars ONTRUZANT[[L40303, L40308] and Adheroza[L52835] are approved.

    Mixtures: PHESGO® 1200 MG/600 MG, PHESGO® 1200 MG/600 MGProducts: OGIVRI 150 MG, HERZUMA 150 MG
  10. Target

    Aclacinomycin 10-hydroxylase RdmB

    go.drugbank.com/bio_entities/BE0002526
    TargetStreptomyces purpurascens

    In vivo and in vitro, RdmB catalyzes the removal of the carboxylic group from the C-10 position of 15-demethoxyaclacinomycin T coupled to hydroxylation at the same C-10 position. … It could also catalyze the removal of the carboxylic group at the C-10 position of 15-demethoxy-epsilon-rhodomycin coupled to hydroxylation at the same C-10 position to yield rhodomycin B.

    Polypeptides: Aclacinomycin 10-hydroxylase RdmBSynonyms: 15-demethoxy-epsilon-rhodomycin 10-hydroxylase